Proteologics
The company IPOed in 2010
About
|
Proteologics is a biopharmaceutical company exploiting the ubiquitin system for the discovery and development of novel therapeutics. Proteologics accomplishes this through identifying correlations between ubiquitin pathway components and pathological conditions. |
 |
|
Proteologics went public on the Tel Aviv Stock Exchange in 2010 |
Established1999 |
FoundersGleb Zilberstein, Dr. Uriel (Uri) Halavee |
ManagementCEO: Josh Levine Director of R&D: Dr. Daniel Taglicht CFO: Esti Hayun Head of Chemistry: Dr. Philippe Nakache |
|
Fields of invesment: |
Contact info:  Website |
 |
 |
 |
|
© 2012 - Giza Venture Capital |
